CAL02

Phase 2Small molecule

EEagle Pharmaceuticals, Inc.

CAL02 is one of 9 small molecule programs targeting Bacterial Pneumonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial PneumoniaActive, not recruiting

Bacterial PneumoniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Bacterial Pneumonia

#DrugCompanyPhaseTrials

Ketek

Biaxin

Levaquin

2 4

Tygacil

PPrism Pharmaceuticals

Amikin

Avycaz

PPhiladelphia Eye Associates

Teflaro

3 8

Polymyxin B

MMahidol University

Phase 3

1 9

CAL02

EEagle Pharmaceuticals, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Pneumonia1 trial

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

Active, not recruiting·EEagle Pharmaceuticals, Inc.·Phase 2·NCT05776004·276 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CAL02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAL02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAL02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eagle Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEagle Pharmaceuticals, Inc.

CAL02

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Pneumonia1 trial

References

Drug Info

Quick Facts

Related News